ginkgol
acid
alkylphenol
constitu
leav
fruit
ginkgo
biloba
ginkgo
biloba
extract
gbe
use
herbal
supplement
sinc
least
centuri
remain
wide
major
constitu
gbe
includ
terpin
trilacton
ginkgolid
b
c
j
bilobalid
flavonoid
glycosid
quercetin
rutin
well
ginkgol
ginkgol
acid
mixtur
sever
acid
common
alkyl
chain
contain
carbon
carbon
chain
unsatur
posit
respect
ginkgol
acid
ga
structur
therefor
design
tabl
ga
shown
pleiotrop
effect
vitro
includ
antitumor
effect
inhibit
lipogenesi
decreas
express
invas
associ
protein
ampk
activ
potenti
rescu
induc
synapt
impair
inhibit
hiv
proteas
activ
well
hiv
viral
ga
also
report
activ
escherichia
coli
staphylococcu
sever
way
ga
work
suggest
includ
sumoyl
inhibit
activ
block
format
inhibit
fatti
acid
nonspecif
sirt
activ
protein
phosphatas
report
ga
show
antivir
activ
herp
simplex
viru
human
cytomegaloviru
hcmv
zika
viru
zikv
primarili
viral
fusion
inhibit
addit
show
inhibit
entri
replicationdefect
nonenvelop
adenoviru
antivir
effect
observ
cytotox
threshold
believ
broad
spectrum
antivir
activ
achiev
inhibit
viral
entri
effect
could
therapeut
util
system
context
sever
acut
viral
diseas
topic
treatment
cutan
viral
lesion
show
broad
spectrum
fusion
inhibit
ga
three
class
fusion
includ
pathogen
human
envelop
virus
class
zikv
hiv
ebov
influenza
viru
iav
class
ii
venezuelan
equin
enceph
viru
veev
semliki
forest
viru
sfv
class
iii
vesicular
stomat
viru
vsv
epstein
barr
viru
ebv
taken
togeth
experi
suggest
ga
inhibit
viral
entri
block
initi
fusion
event
toxic
ga
cell
mem
supplement
fetal
bovin
serum
fb
fig
fig
cell
supplement
fb
cell
infect
hcmv
strain
supplement
fb
inhibitori
concentr
bovin
serum
ga
fig
toxic
ga
hff
cell
mem
medium
supplement
fb
fig
fig
mem
medium
supplement
fb
result
indic
activ
toxic
ga
affect
serum
concentr
medium
see
discuss
assess
effect
ga
hcmv
infect
dilut
made
fig
monolay
human
foreskin
fibroblast
hff
incub
hour
ga
infect
two
cellassoci
clinic
isol
hcmv
neither
viru
produc
extracellular
viru
plate
plaqu
assay
inocul
infect
cell
per
well
treat
medium
contain
ga
vehicl
control
viral
infect
allow
progress
day
quantit
plaqu
reduct
ga
inhibit
infect
respect
assess
effect
ga
plaqu
format
use
strain
produc
cellfre
virion
hff
monolay
plate
pretreat
ga
h
inocul
plaqueform
unit
per
fig
number
plaqu
count
day
determin
predict
previouslydetermin
antivir
effect
appar
furthermor
singl
cell
infect
indic
celltocel
viru
transmiss
result
may
explain
inhibit
secondari
infect
viral
entri
may
target
ga
verifi
result
compar
inhibit
infect
ga
use
plaqu
reduct
assay
pra
similar
pra
ganciclovir
gcv
prefer
antivir
hcmv
drug
choic
result
show
although
strong
inhibit
viru
gcv
still
visibl
plaqu
adjac
cell
show
hcmv
cytopath
effect
indic
celltocel
transmiss
virion
contrari
infect
monolay
treat
ga
display
individu
infect
cell
intact
hff
monolay
fig
thu
indic
cellcel
transmiss
also
test
ga
ga
ga
compound
strong
inhibitori
effect
hcmv
infect
pra
similar
ga
fig
e
none
ga
structur
show
cytotox
activ
concentr
respect
test
ga
rapidli
replic
lytic
dna
viru
zikv
rna
viru
neither
glycoprotein
conserv
common
receptor
hcmv
test
whether
ga
inhibit
design
experi
test
direct
effect
ga
viru
experi
use
cell
pfu
strain
f
treat
hour
ga
vehicl
serum
free
dmem
use
infect
cell
moi
medium
final
concentr
ga
control
viru
origin
treat
vehicl
supplement
also
ga
test
success
viral
infect
cell
product
immedi
earli
earli
late
protein
analyz
western
blot
fig
b
result
show
treat
f
stock
complet
inhibit
viral
replic
indic
lack
protein
synthesi
impli
viral
entri
may
target
ga
direct
treatment
ga
block
downstream
protein
product
test
effect
ga
replic
cell
monolay
grown
confluenc
plate
treat
ga
vehicl
hour
medium
inocul
strain
f
protein
analysi
protein
detect
western
blot
fig
result
show
profound
inhibit
immedi
earli
earli
late
viral
protein
inhibit
full
tempor
rang
protein
impli
inhibit
viral
replic
occur
block
entri
virion
target
cell
evalu
effect
ga
progeni
virion
supernat
strain
infect
vero
cell
moi
collect
h
titer
plaqu
reduct
assay
fig
result
show
signific
decreas
approxim
log
gatreat
cell
titer
test
effect
ga
zikv
infect
nha
grown
confluenc
plate
treat
ga
dmso
hour
without
serum
infect
zikv
strain
moi
next
day
supernat
replac
fresh
medium
contain
ga
dmso
cell
incub
day
viabil
determin
mt
cell
prolifer
assay
promega
cell
harvest
extract
total
rna
quantif
zikv
rna
taqman
base
qrtpcr
result
show
viabil
ga
compar
less
viabil
vehicletr
cell
furthermor
decreas
zikv
rna
observ
ga
fig
b
conclud
ga
inhibit
entri
zika
virion
prevent
nha
cell
death
suggest
mechan
inhibit
appear
target
hsv
hcmv
ga
conserv
among
envelop
virus
homolog
glycoprotein
use
differ
cell
receptor
entri
test
direct
effect
ga
zikv
pfu
zikv
treat
hour
ga
vehicl
medium
use
infect
vero
cell
moi
supernat
collect
hour
postinocul
cell
free
viral
rna
copi
number
determin
fig
result
indic
gatreat
zikv
complet
inhibit
indic
cell
free
zikv
rna
copi
number
suggest
viral
entri
zikv
may
target
ga
direct
treatment
zikv
ga
block
downstream
zikv
rna
product
assess
effect
ga
nonenvelop
viru
also
test
antivir
activ
adenoviru
intern
endocytosi
monolay
vero
cell
incub
hour
medium
contain
ga
dmso
vehicl
cell
inocul
replicationdefect
human
adenoviru
type
contain
gfp
adgfp
viru
moi
medium
contain
ga
hour
inocul
vero
cell
evalu
fluoresc
microscopi
fig
result
show
signific
inhibit
well
inhibit
entri
adenoviru
data
suggest
ga
target
viruscel
fusion
assess
activ
ga
viruscel
fusion
model
viruscel
fusion
fusion
cell
express
viral
fusion
protein
target
cell
cellcel
fusion
monitor
spread
fluoresc
dye
base
crystallograph
identifi
threedimension
structur
fold
viru
fusion
protein
fall
one
three
class
effector
cell
transfect
express
three
class
fusion
protein
tabl
includ
zikv
hiv
ebov
iav
sfv
veev
vsv
ebv
cell
load
calcein
bound
target
cell
either
unlabel
purpos
microscop
identif
load
aqueou
dye
cmac
illustr
ebov
gpinduc
fusion
fig
test
effect
ad
ga
cellcel
fusion
mediat
four
class
two
class
ii
two
class
iii
fusion
protein
eight
protein
ga
complet
block
fusion
fig
furthermor
ebov
gp
treat
ga
ga
ga
fig
ga
deriv
complet
block
fusion
ga
remov
fusion
restor
fig
bar
indic
ga
interfer
fusion
revers
manner
viral
fusion
regardless
fusion
protein
proce
creation
hemifus
intermedi
state
proxim
lipid
monolay
leaflet
membran
contact
one
anoth
merg
distal
monolay
remain
distinct
inhibit
fusion
univers
independ
viral
protein
extrem
unlik
ga
target
fusion
protein
consist
ga
inhibit
creation
hemifus
intermedi
univers
inhibit
would
expect
well
known
agent
confer
posit
spontan
curvatur
lysophosphatidylcholin
lpc
inhibit
fusion
induc
viral
nonvir
fusion
likewis
coneshap
lipid
oleic
acid
oa
neg
spontan
membran
curvatur
favor
hemifus
present
outer
bilay
presenc
reliev
inhibit
addit
oa
togeth
ga
abolish
inhibitori
effect
ga
fig
indic
ga
induc
posit
membran
curvatur
valid
pra
observ
test
whether
effect
downstream
viral
dna
synthesi
hcmv
infect
cell
treat
ga
hff
inocul
hcmv
hour
wash
incub
differ
concentr
ga
vehicl
dna
extract
pool
well
hff
day
post
inocul
analyz
qpcr
target
viral
polymeras
gene
dna
copi
reduc
dose
depend
manner
addit
ga
cultur
medium
fig
although
hcmv
dna
copi
number
reduc
ga
could
secondari
inhibit
viru
entri
rather
direct
inhibit
dna
replic
viral
protein
synthesi
determin
hsvinfect
cell
follow
ga
treatment
untreat
cell
infect
f
moi
hour
allow
virion
intern
cell
wash
medium
supplement
ga
vehicl
viral
replic
evalu
western
blot
detect
protein
although
infect
cell
initi
addit
ga
infect
cell
inhibit
viru
replic
point
exposur
ga
fig
c
observ
effect
could
result
inhibit
secondari
infect
howev
earli
regul
hsv
protein
occur
prior
complet
viral
replic
cycl
suggest
could
secondari
inhibitori
mechan
target
viral
protein
synthesi
ginkgol
acid
commerci
avail
compound
ginkgo
leav
antioxid
activ
ga
report
multipl
therapeut
effect
includ
treatment
cardiovascular
diseas
hiv
infect
bacteri
infect
escherichia
coli
staphylococcu
aureu
suggest
ga
may
oper
sever
pathway
includ
inhibit
fatti
acid
nonspecif
sirt
activ
protein
phosphatas
suppress
activ
induct
pten
tyrosin
protect
synapt
dysfunct
studi
first
report
fusion
inhibitori
effect
ga
envelop
virus
repres
three
class
fusion
protein
inhibit
nonenvelop
human
adenoviru
also
report
potenti
secondari
mechan
action
involv
viral
dna
protein
synthesi
result
consist
previou
report
inhibitori
effect
ga
dna
protein
mechan
action
ga
affect
dna
protein
synthesi
yet
understood
may
bind
host
cell
receptor
activ
differ
cell
signal
pathway
andor
caus
cell
cycl
arrest
may
explain
inhibitori
effect
ga
rapidli
divid
cancer
cell
may
also
enter
cell
work
directli
dna
protein
synthesi
experi
address
question
ongo
assess
effect
ga
infecti
virus
perform
ga
doserespons
experi
cell
treat
differ
ga
concentr
rang
demonstr
dose
depend
effect
ga
hcmv
zikv
effect
ga
test
sever
cell
type
includ
human
epitheli
carcinoma
human
embryon
kidney
hff
nha
normal
human
astrocyt
ga
shown
viral
inhibitori
effect
test
cell
cytotox
within
activ
inhibitori
rang
berg
et
al
evalu
cytotox
mutagen
ga
male
chines
hamster
lung
fibroblast
cell
result
show
toxic
cell
grown
dmem
supplement
fb
hour
ga
concentr
mutagen
effect
ahlemey
et
al
report
ga
induc
neuron
death
activ
protein
phosphatas
chick
embryon
neuron
grow
dmem
bm
hausen
evalu
sensit
capac
ga
guinea
pig
determin
ppm
mm
ga
safe
avoid
induc
allerg
viral
infect
permiss
cell
regularli
perform
mem
medium
supplement
fb
howev
test
activ
toxic
ga
cell
use
research
also
incub
cell
ga
cell
recommend
growth
medium
see
result
fig
result
indic
activ
toxic
ga
affect
serum
concentr
medium
conclud
ga
interact
serum
factor
lower
antivir
activ
research
use
ga
address
issu
futur
experi
vivo
experi
anim
model
need
assess
actual
therapeut
antivir
effect
cytotox
ga
ga
univers
inhibit
viral
proteinmedi
cellcel
fusion
indic
inhibitori
effect
common
fusion
mechan
lpc
also
univers
block
membran
fusion
confer
spontan
posit
curvatur
prevent
hemifus
block
reliev
regardless
fusion
protein
addit
neg
spontan
curvatur
agent
find
oa
reliev
gainduc
inhibit
ebov
gpmediat
fusion
impli
similar
lpc
ga
act
produc
posit
spontan
curvatur
prevent
hemifus
number
rigid
amphipath
fusion
inhibitor
rafi
posit
spontan
curvatur
shown
inhibit
fusion
induc
unrel
viral
fusion
futur
would
interest
measur
valu
spontan
curvatur
ga
rafi
relat
concentr
oa
necessari
reliev
fusion
inhibit
inhibit
nonenvelop
adenoviru
suggest
sinc
ga
affect
lipid
bilay
curvatur
would
predict
affect
endocyt
entri
nonenvelop
viru
adenoviru
addit
report
ga
appear
potenti
secondari
mechan
viral
dna
protein
synthesi
inhibit
would
predict
target
envelop
nonenvelop
virus
conclus
shown
consist
inhibitori
effect
ga
fusion
varieti
envelop
virus
includ
import
pathogen
ebov
hiv
zika
hcmv
ebv
iav
also
shown
inhibit
nonenvelop
human
adenoviru
suggest
potenti
inhibitori
effect
nonenvelop
virus
furthermor
found
ga
might
possibl
inhibit
hcmv
viral
dna
protein
synthesi
secondari
mechan
thu
light
antivir
effect
ga
establish
viral
infect
permiss
cell
ga
potenti
could
use
treat
acut
viral
infect
eg
coronaviru
ebov
zikv
iav
measl
might
determin
use
topic
applic
success
treatment
activ
lesion
eg
vzv
final
approach
ga
usag
inhibit
envelop
viru
infect
fundament
differ
tradit
microbicid
strategi
target
viru
genom
replic
anticip
could
complement
direct
antivir
agent
offer
new
class
inhibitor
envelop
nonenvelop
virus
cell
obtain
american
type
cultur
collect
atcc
rockvil
md
grown
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
cell
obtain
atcc
grown
dmem
supplement
fb
strain
f
limitedpassag
isol
prototyp
strain
use
strain
gener
gift
dr
peter
vero
cell
obtain
atcc
cultur
complet
dmem
cdmem
contain
fb
mm
lglutamin
uml
penicillinstreptomycin
mm
hepe
buffer
fetalderiv
normal
human
astrocyt
nha
lonza
maintain
astrocyt
growth
medium
agm
lonza
supplement
fb
ascorb
acid
rhegf
gentamicin
amphotericin
b
insulin
lglutamin
earli
passag
use
experi
hcmv
studi
perform
use
cellassoci
lowpassag
clinic
isol
resist
firstlin
hcmv
antivir
drug
ganciclovir
gcv
suscept
gcv
addit
experi
perform
use
express
green
fluoresc
protein
produc
extracellular
viru
zikv
strain
obtain
american
type
cultur
collect
atcc
manassa
va
propag
vero
cell
grown
flask
infect
dilut
viral
stock
moi
absenc
fb
medium
remov
replac
h
postinfect
hpi
fresh
cdmem
supernat
collect
hpi
clarifi
centrifug
g
min
filter
surfactantfre
cellulos
acet
membran
mock
infect
supernat
collect
uninfect
vero
cell
prepar
protocol
use
make
viru
stock
viru
titer
focu
assay
briefli
infect
vero
cell
hpi
fix
permeabil
use
cytofixcytoperm
solut
kit
bd
bioscienc
accord
manufactur
instruct
stain
mous
monoclon
antibodi
mab
specif
flaviviru
group
envelop
protein
emd
millipor
clone
follow
incub
antimous
igg
pe
dilut
sampl
run
lsr
ii
flow
cytomet
data
collect
facsdiva
softwar
bd
bioscienc
analyz
use
flowjo
softwar
treestar
human
adenoviru
cat
purchas
vector
biolab
ga
purchas
sigma
aldrich
st
loui
mo
ga
dilut
methanol
dmso
concentr
mm
effect
ga
assay
model
use
studi
compar
vehicletr
ie
methanol
dmso
control
cell
viral
stock
treat
indic
concentr
ga
cell
harvest
indic
time
collect
lowspe
centrifug
rins
pb
resuspend
ripa
lysi
buffer
proteas
inhibitor
complet
proteas
inhibitor
roch
approxim
protein
per
sampl
subject
analysi
protein
electrophoret
separ
denatur
polyacrylamid
gel
electr
transfer
nitrocellulos
sheet
block
bsa
tween
pb
react
primari
antibodi
mous
monoclon
antibodi
goodwin
institut
cancer
research
mous
monoclon
antibodi
use
dilut
mous
monoclon
antibodi
use
dilut
mous
monoclon
antibodi
sigma
use
dilut
membran
react
appropri
secondari
antibodi
conjug
either
alkalin
phosphatas
horseradish
peroxidas
protein
band
visual
tetrazolium
denvil
scientif
inc
ecl
western
blot
detect
reagent
amersham
bioscienc
accord
manufactur
instruct
cell
grown
well
plate
expos
differ
concentr
ga
h
cell
viabil
determin
assay
thermo
fisher
scientif
catalog
number
pairwis
student
ttest
use
compar
outcom
treatment
compar
control
error
bar
sem
n
confluent
vero
cell
flask
infect
hsv
ml
gibco
medium
supplement
heatinactiv
fb
penicillinstreptomycin
medium
multipl
infect
moi
pfucel
incub
gentl
shake
hour
allow
cell
absorb
viru
hour
v
aspir
cell
cultur
vero
cell
gentli
wash
dpb
ml
fresh
fb
medium
ad
cell
incub
day
cell
display
cytopath
effect
cpe
cpe
observ
flask
place
min
allow
warm
room
temperatur
ml
cold
steril
milk
ad
cell
collect
ml
tube
kept
ice
free
viru
particl
cellular
debri
vero
cell
sonic
three
time
let
cell
suspens
cool
ice
min
sonic
second
use
branson
sonifi
microtip
output
set
approxim
power
output
viru
stock
aliquot
transfer
steril
screwcap
cryovial
store
viral
titer
determin
plaqu
assay
ga
incub
monolay
vero
cell
plate
gibco
supplement
heatinactiv
fetal
bovin
serum
penicillinstreptomycin
hour
prior
inocul
follow
incub
supernat
aspir
cell
wash
two
time
dpb
strain
moi
incub
cell
hour
supernat
collect
titer
variou
dilut
collect
supernat
incub
monolay
fresh
vero
cell
plate
shaker
h
allow
viru
attach
enter
cell
supernat
aspir
cell
incub
mgml
human
serum
dmem
dulbecco
modifi
eagl
medium
supplement
fb
penicillinstreptomycin
day
allow
plaqu
format
plaqu
count
cell
fix
methanol
min
room
temperatur
stain
karyomax
giemsa
stain
distil
water
min
room
temperatur
viral
titer
calcul
plaqu
count
express
plaqueform
unit
pfu
ml
cell
free
zikv
medium
pretreat
ga
dmso
hour
pretreat
zikv
use
infect
vero
cell
grown
well
plate
confluenc
moi
hour
infect
cell
wash
twice
warm
dpb
supplement
dmem
supplement
fb
supernat
collect
hour
postinocul
cellfre
viral
rna
copi
number
determin
nha
grown
well
plate
confluenc
treat
ga
h
infect
zikv
moi
supernat
care
remov
replac
hpi
fresh
agm
replenish
ga
concentr
cell
viabil
assess
day
postinocul
celltit
aqueou
one
solut
cell
prolifer
assay
promega
madison
wi
live
cell
care
harvest
extract
rna
rneasi
kit
qiagen
germantown
md
rna
quantifi
use
thermofish
treat
dnasei
sigmaaldrich
min
room
temperatur
remov
dna
contamin
subsequ
dnasei
inactiv
heat
min
cdna
synthes
rna
use
qscript
supermix
quanta
bioscienc
quantit
realtim
pcr
qrtpcr
reaction
perform
solut
contain
taqman
gene
express
master
mix
life
technolog
nm
primer
nm
probe
reaction
perform
appli
biosystem
sequenc
detect
system
thermo
fisher
scientif
use
softwar
reaction
condit
min
min
follow
cycl
min
sampl
run
duplic
triplic
templat
control
includ
wherev
necessari
fold
chang
rna
express
calcul
rel
quantif
use
compar
ct
method
gapdh
endogen
control
primer
probe
design
use
primerquest
tool
integr
dna
technolog
sequenc
primer
follow
zikvfcgctgcccaacacaaggt
zikvr
gctccctttgccaaaaagtccaca
zikvprob
human
specif
gapdhfggtgtgaaccatgagaagtatga
gapdhrgagtccttccacgataccaaag
gapdhprob
hff
grown
well
plate
confluenc
mem
fb
establish
viral
inhibit
two
lowpassag
clinic
strain
via
plaqu
assay
cell
infect
lowpassag
hcmv
clinic
strain
releas
extracellular
viru
display
typic
hcmv
cytopath
effect
cpe
percentag
infect
cell
estim
visual
hff
monolay
dilut
trypsin
cell
use
inocula
hff
monolay
well
plate
day
cultur
plaqu
count
determin
averag
number
plaqu
replic
dilut
optim
dilut
viru
strain
produc
averag
plaqu
per
well
undergon
multipl
passag
produc
extracellular
viru
viral
infect
quantit
determin
pra
cultur
supernat
medium
cell
either
expos
ga
three
hour
prior
inocul
inocul
prior
addit
medium
contain
ga
concentr
mem
fb
one
set
four
well
treat
dmso
vehicl
control
experi
remain
concentr
repres
quadrupl
well
plate
read
begin
day
post
inocul
dpi
determin
ga
concentr
produc
reduct
number
plaqu
rel
vehicl
control
well
data
normal
vehicl
control
probit
analysi
spss
use
obtain
confid
interv
mean
valu
hcmv
infect
monolay
trypsin
pool
termin
pra
dna
extract
pool
monolay
use
blood
gdna
kit
promega
madison
wi
hcmv
dna
quantit
use
valid
inhous
assay
target
dna
reaction
perform
appli
biosystem
thermo
fisher
scientif
monolay
vero
cell
incub
hour
medium
contain
ga
dmso
vehicl
cell
inocul
replicationdefect
human
adenoviru
type
contain
gfp
adgfp
viru
moi
medium
contain
ga
hour
infect
evalu
fluoresc
microscopi
experi
use
cellcel
fusion
system
zikv
hiv
ebov
iva
veev
vsv
sfv
ebv
plasmid
fusion
protein
relat
refer
describ
tabl
nucleat
cellcel
fusion
experi
perform
calceinam
load
effector
cell
express
fusion
protein
cmac
load
target
cell
mix
dye
score
fusion
fusion
experi
viral
protein
perform
previous
describ
ebov
sfv
iav
veev
e
vsv
unless
state
otherwis
ebov
gp
use
fusion
protein
ga
use
inhibit
fusion
shown
fig
ga
inhibit
fusion
eight
test
fusion
protein
figur
document
fusion
blockad
ga
hcmv
plaqu
assay
data
analyz
use
oneway
anova
analysi
spss
n
degre
freedom
group
within
group
f
valu
n
degre
freedom
group
within
group
f
valu
fusion
experi
pairwis
student
ttest
use
compar
outcom
manipul
fusion
compar
control
error
bar
sem
n
hcmv
dna
copi
number
express
percent
control
signific
set
p
p
valu
obtain
use
twotail
ttest
measur
perform
duplic
standard
curv
includ
run
zikv
data
analyz
use
unpair
two
tail
student
test
repres
standard
error
experi
done
independ
least
three
time
valu
p
indic
statist
signific
differ
